Medical Licensing (MD/DO) · Independent exam preparation
Molecular Genetic Pathology: Physician Subspecialty Preparation Guide Study Guide
Practise molecular assay selection, variant interpretation, cancer biomarkers, inherited disease testing and laboratory decisions for ABPath subspecialty preparation.
By CertMedbry · Updated 16 October 2026
Choose appropriate molecular tests, interpret discordant results, calculate risk and recognize laboratory failures through clinically grounded examples. This guide follows the ABPath physician subspecialty pathway for Molecular Genetic Pathology, jointly administered in cooperation with ABMGG. Its 60 concepts selectively cover every weighted domain; the official content specifications remain the full-scope preparation reference and caution that their topic list is not exhaustive.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification and pathway does this guide address?
This guide addresses the ABPath Molecular Genetic Pathology physician subspecialty certification examination. Certification is a joint function of ABPath and ABMGG. The ABPath pathway requires certification in AP/CP, AP or CP and 12 months of ACGME-accredited molecular genetic pathology training, together with applicable general requirements. ABMGG physician diplomates may also qualify for this examination. It is distinct from the Laboratory Genetics and Genomics examination and from general medical licensure.
How many questions are there, and how long is the examination?
The blueprint explicitly updated for 2026 lists 245 questions and a total time of 6 hours 34 minutes. The general examination description rounds these figures to approximately 245 questions and approximately 6½ hours, completed in one day. Use the current daily schedule and candidate instructions for section timing and breaks; the total alone does not establish that breakdown.
Molecular Genetic Pathology Exam Blueprint — Updated for 2026 · Molecular Genetic Pathology — ABPath
How many questions are scored or unscored pretest items?
The official examination documents establish the total question count but do not establish a scored-versus-pretest breakdown. A separate number of scored or unscored questions therefore cannot be stated reliably.
Molecular Genetic Pathology Exam Blueprint — Updated for 2026 · Molecular Genetic Pathology — ABPath
How is the examination delivered, and what item styles appear?
The examination is computer based and administered at Pearson VUE Professional Test Centers. Written and practical questions are combined within sections, and all questions use the single-best-answer multiple-choice format. Items may include pedigrees, karyotypes, sequencing or array data, graphs and other images. The official description does not establish computer-adaptive delivery.
2026 ABPath Booklet of Information · Molecular Genetic Pathology — ABPath
Which blueprint and content-specification versions apply?
The weighted blueprint explicitly states Updated for 2026. The currently linked Molecular Genetic Pathology content specifications are labeled final, with a filename dated November 5, 2025; that filename is not a separately stated effective date. The detailed specifications span foundational through fellow-level knowledge, so subspecialty preparation must extend beyond introductory AP/CP coverage. March 2026 general management specifications supplement relevant management topics, although their overview predominantly addresses primary examinations.
Molecular Genetic Pathology Exam Blueprint — Updated for 2026 · Content Specifications for Examinations — ABPath · Molecular Genetic Pathology Content Specifications — Final · General Management and Informatics Content Specifications — March 2026
What are the approximate official domain weights?
Normal Structure and Function 7%; Molecular Genetic Principles 7%; Techniques and Methods 5%; Assay Performance and Validation 7%; Quality 6%; Ethical, Legal, and Regulatory issues 5%; Indications for testing 4%; Inherited Diseases 10%; Inherited cancer Syndromes 5%; Solid Tumors 11%; Hematopathology 9%; Pharmacogenetics 5%; Infectious Disease 6%; Identity Testing 4%; Histocompatibility 2%; Informatics 4%; Management and Informatics-General 3%. These are approximate examination weights, not guarantees for an individual form.
Molecular Genetic Pathology Exam Blueprint — Updated for 2026
What reference aids and passing-score information are verified?
ABPath states that a codon table and amino-acid abbreviations are available for reference during the molecular genetic subspecialty examination. The January 2026 Booklet of Information states a scaled passing score of 500. This is not a raw percentage, and one scaled point does not correspond to one question.
Molecular Genetic Pathology — ABPath · 2026 ABPath Booklet of Information
How should this selective guide be used with the official outline?
Use these concepts to practise interpretation and laboratory decisions, then work through the complete official content specifications. Remaining areas include hemoglobin and coagulation disorders, cardiovascular genetics, cystic fibrosis, metabolic disorders, APC- and MUTYH-associated polyposis, additional organ-specific tumor biomarkers, mature lymphoid and plasma-cell neoplasms, other drug-metabolizing enzymes, broader microbial sequencing and epidemiology, relationship and forensic testing, and gene therapy. These examples identify omissions rather than exhaust them. The 20 questions and 20 flashcards cover all weighted domains, with additional items in inherited diseases, solid tumors and hematopathology. Such small sets approximate breadth rather than reproduce every percentage.
Molecular Genetic Pathology Exam Blueprint — Updated for 2026 · Molecular Genetic Pathology Content Specifications — Final
Independent educational material organized around the 2026 ABPath blueprint. The questions are original learning drills, and their results do not predict certification performance.
Outline used: ABPath Molecular Genetic Pathology Exam Blueprint, explicitly updated for 2026; currently linked final Molecular Genetic Pathology Content Specifications, filename dated 2025-11-05; 2026 Booklet of Information, updated January 2026. The workbook label maps to this subspecialty certification examination. The assigned canonical slug is preserved. The content specifications do not state a separate effective date.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Normal Structure and Function7%
1.How do HGVS coding coordinates identify a variant precisely?
HGVS coding DNA numbering begins with the A of the translation initiation codon as c.1. Upstream coding-transcript positions use negative numbers, whereas positions beyond the termination codon use an asterisk. Intronic positions are described relative to exon boundaries. A reference accession and version anchor the description to a particular sequence. The discriminating question is whether two descriptions use the same transcript and coordinate system before treating them as equivalent findings.
Apply it
Two laboratories report apparently different coordinates for the same familial variant. Compare transcript accessions and versions, then map both descriptions to their reference sequences before deciding whether the results agree or represent different molecular findings.
Common pitfall: Matching a gene symbol and numerical position is insufficient. Different transcripts can assign different coding coordinates to the same genomic alteration.
Glossary — HGVS Nomenclature · Variant Call Format Specification, Version 4.5
2.How does RNA evidence clarify a suspected splice alteration?
A DNA alteration near a splice junction may cause exon skipping, intron retention, cryptic-site use or no detectable transcript change. Sequence prediction describes a hypothesis; RNA testing can demonstrate the actual junction or transcript population in the tested material. Tissue expression, transcript stability and assay design affect what is observable. Distinguish an experimentally demonstrated RNA consequence from one inferred solely from the DNA position or a computational splice score.
Apply it
A tumor carries an intronic change beside an exon boundary. Junction-spanning RNA reads demonstrate direct joining of the flanking exons, providing evidence of exon skipping that the DNA finding alone could only suggest in this specimen.
Common pitfall: A canonical splice-site location does not specify the exact resulting transcript. Conversely, absent abnormal RNA can reflect tissue expression or transcript degradation.
RNA Splicing — HGVS Nomenclature · The Landscape of MET Exon 14 Skipping Mutations in Patients With Lung Cancer
3.When does an exon deletion preserve the reading frame?
Translation reads coding sequence in successive groups of three nucleotides. Deleting a coding segment preserves the downstream frame when the net coding-length change is divisible by three, provided the relevant exon boundaries and transcript are correctly identified. An in-frame deletion can still remove an essential functional region. A frameshift changes downstream codons and often introduces a premature termination codon; neither label alone establishes the complete biological or clinical consequence.
Apply it
RNA analysis confirms loss of ninety coding nucleotides from a transcript. The deletion preserves the downstream reading frame because ninety is divisible by three, but interpretation must still consider the protein region removed and available functional evidence.
Common pitfall: Counting genomic deletion length can mislead when introns are included. Reading-frame assessment requires the net change in the relevant coding transcript sequence.
Glossary — HGVS Nomenclature · RNA Splicing — HGVS Nomenclature
4.How can a synonymous change alter protein production through splicing?
Coding sequence also contains regulatory information for exon recognition. The synonymous c.840C>T difference in SMN2 exon 7 does not change the encoded amino acid, but alters splicing regulation so that most SMN2 transcripts skip exon 7. The resulting shortened protein is unstable, and each SMN2 copy produces less full-length functional protein than an SMN1 copy. A synonymous annotation therefore describes the direct codon consequence without excluding an effect on RNA processing.
Apply it
A sequence difference preserves the amino acid but lies in an exon involved in regulated splicing. Assess exon inclusion and full-length transcript production rather than assuming that unchanged protein coding automatically means unchanged expression.
Common pitfall: Synonymous does not mean functionally neutral. Codon identity and splice regulation are separate properties of the same sequence.
Technical standards and guidelines for spinal muscular atrophy testing | Genetics in Medicine · RNA Splicing — HGVS Nomenclature
Molecular Genetic Principles7%
5.How does a negative carrier test change prior risk?
Bayesian updating combines prior carrier probability with the probability of the observed test result under carrier and noncarrier states. For a negative test, multiply prior carrier probability by the false-negative probability, then divide by the total probability of a negative result. Sensitivity must match the relevant population and variant spectrum. A negative screen reduces risk rather than automatically eliminating it, especially when the assay misses specific structural configurations or sequence variants.
Apply it
Assume carrier probability is 1/25, sensitivity is 90% and specificity is 100%. After a negative result, residual risk is 0.004 divided by 0.964, approximately 1/241, rather than zero for this hypothetical individual.
Common pitfall: Multiplying prior risk by the false-negative rate gives the numerator, not the exact posterior probability. The denominator must include all ways a negative result occurs.
Molecular Genetic Pathology Content Specifications — Final · Pan-ethnic Carrier Screening and Prenatal Diagnosis for Spinal Muscular Atrophy
6.Why does cis-versus-trans phase matter in recessive disease?
Two variants in an autosomal recessive disease gene can affect opposite homologues in trans or the same homologue in cis. Trans configuration can establish biallelic involvement when both variants have appropriate pathogenic evidence; cis configuration leaves the other allele potentially functional. Parental segregation, informative reads or other validated phasing methods can resolve the arrangement. The number of detected variants therefore cannot substitute for determining which physical alleles carry them in the patient.
Apply it
A child has two pathogenic variants in a recessive disease gene. Both are inherited together from one parent, while the other parent lacks them; the result does not yet establish disease-causing variants on both homologues in this child.
Common pitfall: Two heterozygous calls do not necessarily mean compound heterozygosity. Variant classification and physical phase answer different questions and both can affect interpretation.
7.How does mosaicism alter tissue selection and allele fractions?
Postzygotic alterations can create genetically distinct cell populations within one individual. Their representation varies among tissues, so a negative blood result may not exclude an alteration enriched in affected tissue. Under a simple diploid model, a heterozygous variant present in a fraction of cells has approximately half that cellular fraction as its variant allele fraction. Copy-number changes, sampling and technical bias can disrupt this relationship and must be evaluated before estimating mosaic burden.
Apply it
An affected skin biopsy shows a variant at 15% allele fraction while blood testing is negative. With diploidy and no allelic bias assumed, approximately 30% of sampled skin cells may carry the heterozygous alteration in that specimen.
Common pitfall: Allele fraction is not automatically the percentage of affected cells. Tissue mixture, copy number and assay sensitivity can each change that relationship substantially.
Molecular Genetic Pathology Content Specifications — Final · AMP/CAP Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels
8.Why does an unaffected relative not always exclude dominant inheritance?
Penetrance describes whether a genotype produces a recognizable phenotype; expressivity describes the phenotype's range or severity among affected individuals. Reduced or age-dependent penetrance permits a pathogenic dominant variant to occur in an apparently unaffected relative. Risk assessment must therefore consider the person's age, phenotype definition and disease-specific evidence. A transmitting parent without current manifestations does not by itself refute pathogenicity or establish that a child's finding arose de novo in the family.
Apply it
A young adult parent carries the same cancer-predisposition variant as an affected child but has no cancer history. Interpret the segregation using age-dependent penetrance rather than treating the parent's present health as evidence against the variant.
Common pitfall: A 50% transmission probability is not necessarily a 50% probability of developing disease. Transmission and penetrance are separate components of an individual's risk.
Molecular Genetic Pathology Content Specifications — Final · BRCA Gene Changes: Cancer Risk and Genetic Testing — NCI
Techniques and Methods5%
9.Which alterations can chromosomal microarray reliably address?
Chromosomal microarray measures relative genomic dosage across interrogated regions and can detect deletions or duplications within its validated resolution. SNP-containing arrays may additionally reveal regions of homozygosity and informative allelic patterns. A truly balanced rearrangement has no net dosage change and may escape detection. Routine arrays also do not provide comprehensive nucleotide-level sequencing. Choose the method by the suspected alteration class rather than assuming that genome-wide coverage means every genomic change is visible.
Apply it
A patient has a normal microarray but a family history suggesting a balanced translocation. A chromosome-based structural assessment can address the remaining question because a dosage-neutral rearrangement may produce no abnormal array signal at all.
Common pitfall: Genome-wide sampling is not universal variant detection. A normal array cannot exclude balanced rearrangements, small sequence variants or all forms of low-level mosaicism.
Consensus Statement: Chromosomal Microarray Is a First-Tier Clinical Diagnostic Test
10.How can PCR allele dropout create a misleading genotype?
PCR depends on adequate primer binding and amplification of each relevant allele. A variant beneath a primer, a large insertion or unfavorable amplification kinetics may selectively suppress one allele. The remaining allele can then appear falsely homozygous or a true variant may be missed. Discordant segregation or unexpectedly clean sequence can suggest dropout. An alternative primer placement or method with different analytical vulnerabilities can test whether the apparent genotype reflects selective amplification in that assay.
Apply it
A child's reported homozygous sequence variant is inconsistent with parental results. Reanalysis using primers outside the original binding regions reveals a second allele, demonstrating that selective amplification produced the original misleading genotype rather than an unexpected inheritance event.
Common pitfall: Repeating the same primers may reproduce the same error. Confirmation is strongest when the alternative assay does not share the suspected failure mechanism.
Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions · Molecular Genetic Pathology Content Specifications — Final
11.How do repeat sizing and methylation assays answer different questions?
Repeat sizing estimates the number or distribution of repeat units, whereas methylation analysis assesses an epigenetic state associated with gene regulation. In FMR1 testing, both repeat expansion and methylation can influence interpretation. An assay optimized for ordinary-sized alleles may not fully characterize a large expansion, and a methylation result alone does not precisely size the repeat. Select complementary methods according to the suspected size range, mosaicism and information needed for the report.
Apply it
An FMR1 assay detects evidence of a large expansion but cannot accurately size it or determine methylation. Additional validated characterization should resolve the clinically relevant expansion and methylation questions before a complete interpretation is issued to the family.
Common pitfall: An amplification product from one allele does not establish that every expanded allele was detected. Repeat size and methylation are related but distinct measurements.
Laboratory Testing for Fragile X, 2021 Revision — ACMG Technical Standard · FMR1 Disorders — GeneReviews
Assay Performance and Validation7%
12.How does tumor fraction affect the expected variant allele fraction?
For a clonal heterozygous variant in a diploid tumor region without copy-number change, expected variant allele fraction is approximately half the tumor-cell fraction when normal cells are diploid. This estimate links specimen selection to analytical sensitivity. Subclonality, copy-number alterations and loss of heterozygosity change the expectation. A negative result becomes less informative when the anticipated variant fraction falls below the assay's validated detection capability for the relevant alteration class in that specimen.
Apply it
A specimen contains 20% tumor cells and is tested for a clonal heterozygous alteration in a diploid region. The expected allele fraction is about 10%, so a method validated only above 15% may miss it despite successful sequencing.
Common pitfall: Tumor percentage and variant allele fraction are different quantities. Applying the half-fraction approximation without checking ploidy or clonality can misjudge whether testing is adequate.
AMP/CAP Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels
13.What does a validated limit of detection actually establish?
A limit of detection describes the lowest analyte level detected with a specified probability under validated conditions. It is an assay-performance claim supported by replicate testing, not the smallest signal ever observed. Different variant classes and sequence contexts may have different detection limits. Specimen quality and input also matter. Interpret a low-level result against the relevant validated conditions rather than applying a single sensitivity statement indiscriminately to substitutions, indels, fusions and copy-number changes.
Apply it
A panel detects one deletion at 2% allele fraction during development but lacks adequate replicate support there. That observation does not justify a 2% detection-limit claim; validation must establish reliable performance for the intended variant class and conditions.
Common pitfall: One successful low-level detection demonstrates possibility, not reproducibility. Read depth alone also cannot establish a detection limit when systematic errors or molecule scarcity dominate.
AMP/CAP Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels
14.How do accuracy, precision and clinical sensitivity differ?
Accuracy concerns agreement with an accepted reference result, while precision concerns consistency among repeated measurements. Analytical sensitivity concerns detection of the target under specified assay conditions; clinical sensitivity concerns identifying individuals with the condition of interest. These properties answer different questions. An assay can reproducibly produce an incorrect result or accurately detect its target while missing disease caused by alteration types outside its design. Validation must connect each performance claim to the intended clinical use.
Apply it
Repeated measurements closely agree, yet all differ from a reference material's assigned value. The assay demonstrates good precision but a systematic accuracy problem, prompting investigation of calibration or method bias before patient results are considered reliable.
Common pitfall: Consistent results are not necessarily correct results. Likewise, excellent analytical detection of one variant does not establish high clinical sensitivity across a genetically heterogeneous disorder.
Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions · AMP/CAP Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels
15.When should a worked germline interpretation remain a variant of uncertain significance?
Analytical confirmation establishes that a variant is present; classification asks whether it causes disease. Consider a hypothetical BRCA2 missense variant with no established clinical classification, no informative segregation or functional data, and only rarity plus computational predictions suggesting damage. These observations do not establish pathogenicity, so the finding remains a variant of uncertain significance. Rarity is compatible with both benign and pathogenic variation, and agreement between prediction programs does not substitute for independent clinical or functional evidence.
Apply it
The hypothetical variant is confirmed by a second method, but the evidence for its disease relationship remains unchanged. Retain the uncertain classification rather than upgrading it because detection is reproducible. Report the unresolved significance and base current risk assessment on established personal and family history.
Common pitfall: A technically convincing call can still have uncertain clinical significance. Neither the word missense nor several damaging predictions independently establishes a pathogenic result.
BRCA Gene Changes: Cancer Risk and Genetic Testing — NCI · Molecular Genetic Pathology Content Specifications — Final
Quality6%
16.How does an internal amplification control distinguish inhibition from absence?
An internal amplification control tests whether a reaction can amplify a control target under the assay's specified interpretation rules. When both pathogen target and required control fail, inhibition or another reaction failure can make the target result uninterpretable. A valid negative requires the appropriate controls to support the absence claim. Strong target amplification can affect control behavior in some assay designs, so control interpretation must follow validated assay-specific criteria rather than a universal rule for every reaction.
Apply it
A bacterial resistance PCR has no target signal and no required internal-control signal, although external controls pass. Treat the specimen result as invalid and investigate inhibition or processing failure rather than reporting that the resistance target is absent.
Common pitfall: Passing external controls proves that the run can work; it does not prove that each specimen reaction was free of inhibitors or processing failure.
Laboratory Testing for KPC and NDM in Gram-negative Bacteria — CDC
17.Which contamination controls localize an unexpected molecular signal?
Contamination can enter during collection, extraction, reagent preparation or amplification setup. A no-template control examines contamination introduced into the amplification mixture, whereas an extraction blank also passes through extraction. Their patterns help localize a problem but do not identify every possible contamination source. Physical workflow separation and appropriate controls reduce carryover risk. Unexpected low-level positives should be assessed in relation to control results, batch layout and reproducibility before they are accepted as patient findings.
Apply it
An extraction blank and several low-burden specimens show the same unexpected target, while a separately prepared amplification blank is negative. Investigate contamination during extraction or upstream handling before accepting those weak specimen signals as independent true positives.
Common pitfall: A negative no-template control does not exclude contamination introduced before PCR setup. Controls must sample the workflow stage whose reliability is being evaluated.
Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions
18.Why should quantitative controls monitor trends rather than only pass limits?
Quantitative controls provide information about measurement stability across runs. A gradual shift can reveal calibration drift, reagent deterioration or an instrument change before an individual result crosses an acceptance boundary. Interpretation should use predefined control procedures and investigate sustained patterns. A control near a clinically important decision level can be especially informative. Successful amplification alone does not establish stable quantification, because a reaction may remain detectable while its measured value changes systematically over time.
Apply it
A molecular monitoring assay's control remains within limits, but its measured concentration rises steadily over several runs. Review the trend for systematic change and investigate relevant reagents or calibration before attributing similar patient shifts to disease progression alone.
Common pitfall: Treating every in-range value as equivalent can miss drift. A binary positive control cannot establish that a quantitative assay remains numerically stable over time.
Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions · AMP/CAP Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels
19.How should an unexpected quality-control failure affect result release?
Quality-control acceptance criteria define when patient results are supported by the analytical process. A relevant control failure requires assessment of the affected run or specimens before release, even when some patient signals appear plausible. The investigation should consider whether the failure affects detection, quantification or a specific assay component. Corrective work must restore acceptable performance and determine the disposition of affected results. Repeating a control without understanding a persistent problem can conceal rather than resolve failure.
Apply it
A low-positive control repeatedly fails while high-positive specimens amplify. Hold affected negative interpretations because sensitivity near the detection boundary is unsupported, then investigate the failure and repeat appropriate testing after acceptable performance has been restored for the run.
Common pitfall: Strong patient positives do not validate weak-target detection. A sensitivity-related control failure can selectively undermine negatives even when abundant targets remain readily detectable.
Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions · AMP/CAP Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels
Ethical, Legal, and Regulatory issues5%
20.What should informed consent clarify before germline testing?
Germline testing can affect medical decisions, relatives and future risk assessment. Consent should explain the purpose and scope of testing, possible result categories, important limitations and relevant family implications. Broader testing may also raise choices about additional findings. Understanding must precede testing rather than be reduced to obtaining a signature. A useful discriminating question is whether the patient understands what the selected test can establish and what uncertainty or unexpected information it may leave.
Apply it
An unaffected person requests broad hereditary cancer testing without understanding uncertain results. Explain pathogenic findings, uninformative negatives and uncertain variants, including implications for relatives, before confirming that the planned scope matches the person's informed preferences for testing.
Common pitfall: Consent for a targeted familial variant does not automatically establish understanding of a broad panel's additional findings. The discussion should match the actual test scope.
Genetic Testing FAQ — NHGRI · BRCA Gene Changes: Cancer Risk and Genetic Testing — NCI
21.Which insurance protections does United States GINA provide?
In the United States, the Genetic Information Nondiscrimination Act addresses specified uses of genetic information in health insurance and employment. It does not provide the same protections for life, disability or long-term care insurance. These boundaries matter when discussing predictive testing with an unaffected individual. GINA is not a universal privacy law or a worldwide rule. Counseling should distinguish its federal protections from other applicable laws without promising comprehensive protection against every possible use of genetic information.
Apply it
An unaffected adult considering predictive testing asks whether the result is protected in every insurance application. Explain the federal health-insurance and employment protections while identifying life, disability and long-term care insurance as outside GINA's corresponding protections.
Common pitfall: Saying genetic discrimination is prohibited without qualification overstates GINA. Its jurisdiction and covered settings must be distinguished from all insurance and employment situations.
22.Why should an uncertain variant not be treated as a pathogenic result?
A variant of uncertain significance reflects insufficient or conflicting evidence for a reliable pathogenic or benign classification. It does not establish a molecular diagnosis or justify managing an unaffected relative as a confirmed carrier of a disease-causing variant. Clinical care should use established personal and family risk information while uncertainty remains. Additional evidence may eventually change classification. Communication should explain what is unresolved without converting a laboratory observation into a stronger medical claim than the evidence supports.
Apply it
A healthy relative asks for irreversible risk-reducing intervention because a family member's BRCA report contains an uncertain variant. Explain that the finding does not establish pathogenic carrier status and assess the relative's established clinical and family risk separately.
Common pitfall: The word variant is not synonymous with disease-causing mutation. A compelling family history also does not automatically resolve the classification of a particular uncertain finding.
Indications for testing4%
23.How should the clinical question determine the molecular test?
A useful test must interrogate the alteration class relevant to the clinical question in an appropriate specimen. Sequence analysis, dosage testing, repeat analysis and methylation testing have different strengths. Diagnostic testing asks whether a molecular cause explains current findings; predictive testing addresses future risk, and monitoring measures an established disease marker over time. Choosing the broadest available panel does not guarantee the needed mechanism is covered. Match phenotype, suspected biology and analytical scope before ordering.
Apply it
A child has findings strongly suggesting a repeat-expansion disorder, but a proposed panel only evaluates substitutions and small indels. Select testing validated for the suspected expansion rather than assuming that inclusion of the gene ensures adequate assessment.
Common pitfall: A gene's presence on a panel does not establish coverage of every pathogenic mechanism. The assay's alteration classes and specimen requirements remain decisive.
Genetic Testing FAQ — NHGRI · Laboratory Testing for Fragile X, 2021 Revision — ACMG Technical Standard
24.When is targeted familial testing more informative than an unexplained negative panel?
When a pathogenic familial variant is known, targeted testing can determine whether a relative inherited that specific alteration. A negative result then has a defined relationship to the established familial cause, assuming reliable detection. By contrast, a negative panel in an unaffected person without an identified family variant may remain uninformative about the family's underlying susceptibility. Whenever feasible, testing an informative affected relative first can distinguish a true familial negative from an unexplained absence of findings.
Apply it
Two unaffected siblings request testing after their mother's cancer. If her pathogenic variant is known, testing that variant answers inheritance directly; if no affected relative has been tested, a negative panel may not explain the familial cancer pattern.
Common pitfall: All negative genetic reports do not carry the same reassurance. Their meaning depends on whether the family's causal variant was already established and adequately assessed.
BRCA Gene Changes: Cancer Risk and Genetic Testing — NCI · Genetic Testing FAQ — NHGRI
Inherited Diseases10%
25.How do FMR1 premutations and full mutations differ mechanistically?
FMR1 repeat categories distinguish different biological and clinical contexts. Premutations generally contain approximately 55–200 CGG repeats and can be associated with RNA-mediated disorders and transmission instability. Full mutations generally exceed 200 repeats and are commonly associated with abnormal methylation and reduced FMR1 expression in fragile X syndrome. Size and methylation mosaicism can complicate a simple category assignment. Interpret repeat distribution and methylation together rather than assuming that every expanded allele causes disease through the same mechanism.
Apply it
An adult's result identifies a premutation-range FMR1 expansion. Explain that this differs mechanistically from a typically methylated full mutation and requires interpretation of premutation-associated risks and reproductive transmission rather than automatic diagnosis of classic fragile X syndrome.
Common pitfall: Larger than normal does not mean fully silenced. Premutation-associated disease and full-mutation fragile X syndrome should not be collapsed into one molecular mechanism.
Laboratory Testing for Fragile X, 2021 Revision — ACMG Technical Standard · FMR1 Disorders — GeneReviews
26.Why can repeat interruptions refine FMR1 transmission assessment?
CGG repeat length is important for FMR1 instability, but the internal repeat structure also matters. AGG interruptions can stabilize the repeat tract and modify expansion risk during maternal transmission, particularly for some smaller premutations. Their value is contextual rather than absolute: interruption analysis does not replace repeat sizing, parental information or appropriate counseling. A precise reproductive interpretation should distinguish the measured repeat structure from the separate question of whether the tested individual has a full mutation.
Apply it
Two women have similarly sized FMR1 premutations but different AGG interruption patterns. Their transmission assessments need not be identical, so incorporate interruption information when available rather than assigning risk solely from the total CGG repeat count.
Common pitfall: An AGG interruption does not guarantee stable transmission. Conversely, absence of interruptions is a risk modifier rather than proof that expansion will occur.
FMR1 Disorders — GeneReviews · Laboratory Testing for Fragile X, 2021 Revision — ACMG Technical Standard
27.How do SMN1 diagnosis and SMN2 copy number answer different questions?
Spinal muscular atrophy commonly results from biallelic loss of functional SMN1. Testing must distinguish SMN1 from the highly homologous SMN2 locus and recognize what dosage analysis can establish. SMN2 copy number can modify phenotype but is not itself proof of the SMN1 disease genotype. If a compatible patient has only one detected SMN1 deletion, sequence-level analysis may address a pathogenic alteration on the other allele. Diagnostic interpretation therefore separates causal SMN1 findings from modifier information.
Apply it
An infant with a compatible neuromuscular phenotype has one SMN1 copy detected. Investigate whether the remaining copy contains a pathogenic sequence variant rather than considering a favorable SMN2 copy count sufficient to resolve the diagnostic question in this child.
Common pitfall: SMN2 is a modifier, not an interchangeable substitute for establishing the SMN1 genotype. Dosage analysis also does not detect every possible pathogenic sequence alteration.
Spinal Muscular Atrophy — GeneReviews · Pan-ethnic Carrier Screening and Prenatal Diagnosis for Spinal Muscular Atrophy · Technical standards and guidelines for spinal muscular atrophy testing | Genetics in Medicine
28.Why can two SMN1 copies leave residual carrier risk?
A dosage result of two SMN1 copies does not determine their chromosomal arrangement. The usual noncarrier arrangement places one copy on each homologue, but a silent carrier can have two copies in cis and no copy on the other homologue. Sequence variants and assay limitations can leave additional residual risk. Linked markers or family studies may refine interpretation when appropriately validated, but their informativeness varies. Report copy number separately from certainty about carrier status for the individual.
Apply it
A person with an affected sibling receives a two-copy SMN1 screening result. Review the family's alleles and the possibility of a two-plus-zero configuration before concluding that the result excludes carrier status or removes the family's reproductive risk.
Common pitfall: Total copy number is not haplotype phase. A two-copy result lowers risk in many settings but does not universally exclude a silent carrier.
Pan-ethnic Carrier Screening and Prenatal Diagnosis for Spinal Muscular Atrophy · Spinal Muscular Atrophy — GeneReviews
29.How do parent-of-origin and methylation distinguish Prader-Willi and Angelman mechanisms?
At 15q11–q13, Prader-Willi syndrome results from loss of the paternal functional contribution, whereas Angelman syndrome involves loss of maternal UBE3A function in neurons. At the diagnostically informative SNURF-SNRPN region, the maternal allele is methylated and the paternal allele is unmethylated. A maternal-only methylation pattern supports Prader-Willi syndrome; a paternal-only pattern supports a methylation-detectable Angelman mechanism. Deletion, uniparental disomy and imprinting defects can produce these patterns. Normal methylation does not exclude Angelman syndrome caused by a UBE3A sequence variant.
Apply it
A hypotonic infant has a maternal-only methylation pattern with normal 15q11–q13 dosage. This supports Prader-Willi syndrome but does not distinguish maternal uniparental disomy from an imprinting defect. Informative parental marker studies showing exclusively maternal inheritance support disomy; biparental inheritance supports an imprinting defect and prompts assessment for an imprinting-centre deletion.
Common pitfall: Abnormal methylation with normal dosage is not proof of uniparental disomy. Mechanism matters for recurrence: a familial imprinting-centre deletion can confer a 50% recurrence risk when carried by the relevant transmitting parent.
30.How does mitochondrial heteroplasmy affect molecular diagnosis?
Heteroplasmy is the coexistence of different mitochondrial DNA populations within an individual or specimen. Variant proportions can differ among tissues and change with biological selection, so a blood measurement may not represent the most affected tissue. Disease expression also depends on the particular alteration and tissue vulnerability rather than a universal threshold. A negative or low-level blood result must therefore be interpreted with specimen choice and assay sensitivity in mind when the clinical findings suggest mitochondrial disease.
Apply it
An adult with diabetes, sensorineural hearing loss and maternal family history has negative blood testing for MT-TL1 m.3243A>G. This variant can decline in blood with age; appropriately validated urine testing can provide a more informative assessment than simply repeating the same blood assay.
Common pitfall: A single heteroplasmy percentage is not a universal severity score. Different tissues and variants can have different relationships between measured allele fraction and dysfunction.
Inherited cancer Syndromes5%
31.How can an EPCAM deletion cause Lynch syndrome?
Certain germline deletions removing the 3′ transcription-termination region of EPCAM permit read-through toward neighboring MSH2 while preserving MSH2 coding sequence. This can induce MSH2 promoter methylation and silencing in tissues expressing EPCAM, creating mismatch-repair deficiency without a pathogenic MSH2 coding variant. The effect depends on the deletion and its genomic context. This mechanism supports structural evaluation of EPCAM when the tumor phenotype suggests MSH2 pathway loss and conventional MSH2 coding analysis does not explain the finding.
Apply it
Tumors in a family repeatedly lose MSH2 and MSH6 expression, but MSH2 sequencing is unrevealing. Testing capable of detecting relevant EPCAM deletions can identify a germline mechanism that a coding-only MSH2 assay would leave unresolved in that family.
Common pitfall: Not every EPCAM deletion has the same effect. The relevant terminal region and relationship to MSH2 must be considered before assigning this mechanism.
Recurrence and Variability of Germline EPCAM Deletions in Lynch Syndrome
32.Why does a tumor BRCA finding require separate germline interpretation?
A pathogenic BRCA alteration detected in a tumor may be acquired, inherited or otherwise require clarification in an appropriate non-tumor specimen. Tumor analysis can identify a finding relevant to cancer biology without establishing constitutional carrier status. Conversely, a negative tumor result does not necessarily replace a clinically indicated germline evaluation. Distinguish the immediate tumor-testing question from inherited risk to the patient and relatives, and explain why confirmation in a suitable germline specimen may change family counseling.
Apply it
Tumor sequencing identifies a pathogenic BRCA2 alteration in a patient with cancer. Arrange appropriate germline evaluation before offering relatives predictive testing for an established familial variant, because the tumor finding alone does not show that it was inherited.
Common pitfall: An allele fraction near 50% does not prove germline origin in tumor tissue. Tumor purity and copy-number changes can produce overlapping somatic allele fractions.
33.How does the BRCA tumor-suppressor model connect inherited susceptibility to somatic tumor development?
BRCA1 and BRCA2 encode proteins involved in DNA repair. A person with an inherited pathogenic variant usually retains a functioning copy on the other homologue. Somatic loss or inactivation of that remaining copy can leave a cell without sufficient BRCA function and contribute to tumor development. This separates inherited susceptibility, present constitutionally, from the additional events acquired by an individual tumor.
Apply it
A germline specimen is heterozygous for a pathogenic BRCA2 variant, while the tumor shows loss of the remaining wild-type allele. The findings fit constitutional susceptibility followed by somatic loss of the second functional copy. They do not mean that the tumor's additional alteration is inherited by relatives.
Common pitfall: Loss of heterozygosity describes an allelic change; its functional significance depends on which allele remains. Retention of the wild-type allele differs from retention of only the pathogenic allele.
Solid Tumors11%
34.Why does expanded RAS testing matter in colorectal cancer?
Activating RAS alterations can maintain downstream signaling despite blockade of the upstream epidermal growth factor receptor. Expanded assessment for colorectal anti-EGFR selection includes both KRAS and NRAS: exon 2 codons 12 and 13, exon 3 codons 59 and 61, and exon 4 codons 117 and 146. A negative restricted assay does not establish expanded RAS wild-type status. Verify that the report explicitly covers these regions in both genes.
Apply it
A report lists KRAS exon 2 codons 12/13 and NRAS exon 2 codons 12/13 as negative. Coverage remains incomplete: both genes still require exon 3 codons 59/61 and exon 4 codons 117/146. A KRAS exon 2-only report also leaves NRAS exon 2 unassessed.
Common pitfall: A report saying KRAS negative may describe only a small tested region. The gene name alone does not establish adequate predictive-biomarker coverage for treatment selection.
ASCP/CAP/AMP/ASCO Colorectal Cancer Molecular Biomarkers — Summary of Recommendations
35.How does RNA testing demonstrate MET exon 14 skipping?
MET exon 14 skipping is a transcript consequence that can arise from diverse DNA alterations affecting splicing. A DNA assay must cover and recognize the relevant alteration spectrum to infer this event effectively. RNA testing can directly identify the junction joining the exons flanking exon 14, provided transcript quality and expression are adequate. The decisive distinction is between a genomic alteration capable of affecting splicing and observed expression of the skipped transcript in the tested tumor.
Apply it
A lung tumor has an unusual intronic MET alteration with uncertain splice impact. A validated RNA assay detects the exon 13-to-exon 15 junction, directly supporting exon 14 skipping rather than relying only on the DNA variant's location.
Common pitfall: A negative DNA panel may reflect incomplete intronic coverage, while a negative RNA assay may reflect poor RNA quality. Neither modality has unlimited sensitivity.
The Landscape of MET Exon 14 Skipping Mutations in Patients With Lung Cancer · RNA Splicing — HGVS Nomenclature
36.How should MSI and MLH1 loss be interpreted in colorectal carcinoma?
Microsatellite instability reflects altered repeat lengths arising when mismatch repair fails; immunohistochemistry instead assesses the presence of particular repair proteins. A colorectal carcinoma with MSI-high status and MLH1 loss has evidence of repair deficiency, but this does not establish inherited Lynch syndrome. In an MLH1-deficient colorectal tumor, BRAF V600E strongly favors sporadic pathogenesis. Absence of that alteration leaves Lynch risk unresolved and cannot establish a germline diagnosis.
Apply it
An MSI-high colorectal carcinoma lacks MLH1 and carries BRAF V600E. Interpret the tumor as mismatch-repair deficient with findings strongly favoring a sporadic cause. If BRAF is wild type, further etiologic assessment is still needed; wild-type BRAF alone does not demonstrate a constitutional MMR variant.
Common pitfall: MSI status, protein loss and hereditary origin answer different questions. Do not transfer the colorectal BRAF triage rule indiscriminately to other organs.
ASCP/CAP/AMP/ASCO Colorectal Cancer Molecular Biomarkers — Summary of Recommendations · Molecular Genetic Pathology Content Specifications — Final
38.Why must low-frequency tumor variants be assessed for artifacts?
A low-frequency variant may reflect a true subclone, but sequencing errors and specimen-related DNA damage can create similar signals. Confidence depends on validated performance, independent molecule support, strand distribution, local sequence context and specimen quality. High read depth cannot remove systematic artifacts by itself. Evaluate the evidence pattern and the assay's established error characteristics before assigning biological meaning, particularly when the observed fraction approaches the detection boundary or the result would materially influence treatment.
Apply it
A low-frequency substitution appears only in reads from one orientation in a damaged specimen. Review the assay's artifact criteria and independent supporting evidence before reporting a subclone, even though the total read depth at that position is high.
Common pitfall: Thousands of reads may descend from few original molecules. Read count and independent molecular evidence are not interchangeable measures of confidence for a low-frequency call.
AMP/CAP Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels
39.What molecular decision follows an equivocal HER2 immunostain in invasive breast carcinoma?
HER2 immunohistochemistry measures protein expression, whereas in situ hybridization assesses gene amplification. In invasive breast carcinoma, an IHC 2+ result requires reflex ISH assessment rather than being accepted as HER2-positive for overexpression/amplification. The resulting interpretation must retain the actual IHC score and ISH finding. These distinctions follow the [ASCO/CAP breast HER2 guidance](https://www.cap.org/cap-guidelines/her2-testing-in-breast-cancer-2023-guideline-update/).
Apply it
An invasive breast carcinoma is IHC 2+ and has an unequivocally nonamplified result under the applicable ISH algorithm. This does not establish conventional HER2 positivity for protein overexpression or gene amplification. Preserve both results because specific antibody-drug conjugate indications can use expression categories below that threshold.
Common pitfall: A negative overexpression/amplification classification does not mean the tumor expresses no HER2 protein or excludes every HER2-directed treatment indication. Organ-specific scoring and the particular therapeutic claim matter.
Hematopathology9%
41.How do FLT3 duplications, kinase-domain substitutions and AML fusions require different interpretation?
FLT3 internal tandem duplications add a duplicated sequence tract, whereas kinase-domain substitutions such as p.Asp835Tyr alter a codon without creating a large insertion. Algorithms validated for substitutions and small indels can miss long FLT3 duplications, including events exceeding 300 bases, because inserted reads align poorly or are clipped. A substitution assay must cover the relevant kinase-domain site and detect its allele fraction; an ITD fragment assay does not automatically establish substitution coverage. NPM1 and CEBPA sequence assessment and AML fusion testing address additional questions.
Apply it
An AML specimen has a valid negative FLT3 kinase-domain result, but the panel lacks validated long-ITD detection. Add validated ITD testing, such as fragment analysis. Separately, abnormal promyelocytes with coagulopathy warrant urgent PML::RARA assessment to establish the APL genetic subtype. [ELN APL recommendations](https://pmc.ncbi.nlm.nih.gov/articles/PMC6509567/) support immediate ATRA on clinical suspicion while confirmation proceeds.
Common pitfall: A FLT3-negative summary is incomplete without knowing which alteration classes were assessed. Neither a kinase-domain negative nor an ITD negative excludes PML::RARA, RUNX1::RUNX1T1 or CBFB::MYH11.
Molecular Genetic Pathology Content Specifications — Final · AMP/CAP Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels
42.How should JAK2, CALR and MPL findings be interpreted in suspected myeloproliferative disease?
Detection establishes the presence of a particular variant; driver interpretation establishes its disease-associated biological significance. A characterized acquired activating driver such as JAK2 V617F supports clonal hematopoiesis, but an MPN diagnosis and subtype still require the blood counts, marrow morphology and clinical exclusions specified by the [International Consensus Classification](https://doi.org/10.1182/blood.2022015850). An uncertain JAK2, CALR or MPL finding cannot supply equivalent driver evidence merely because its gene is associated with MPN.
Apply it
Persistent thrombocytosis with suspicious marrow findings and negative JAK2 V617F testing leaves relevant CALR and MPL drivers unassessed. Conversely, detecting JAK2 V617F does not by itself distinguish essential thrombocythemia, polycythemia vera and primary myelofibrosis. For a possible constitutional variant, apply the ACMG/AMP Mendelian classification framework rather than assuming an acquired driver.
Common pitfall: Benign, uncertain, constitutional and established acquired driver findings have different meanings. The ACMG/AMP distinction between uncertain and pathogenic Mendelian variants reinforces that analytical detection alone does not establish causality; it is not itself a somatic MPN diagnostic scheme.
Molecular Genetic Pathology Content Specifications — Final · Standards_Guidelines_for_the_Interpretation_of_Sequence_Variants.pdf
43.How do CML response thresholds and ABL1 control transcripts determine a defensible response category?
Identify the BCR::ABL1 transcript at diagnosis so monitoring targets the patient's fusion; atypical transcripts may require an individualized approach. For appropriately measured standard transcripts on the International Scale, major molecular response is ≤0.1%. ELN 2025 Table 3 defines MR4 as ≤0.01% with at least 10,000 ABL1 control transcripts and MR4.5 as ≤0.0032% with at least 32,000. Adequate control material is required whether BCR::ABL1 is detected or undetectable. These ABL1 minima cannot simply be substituted for those of another reference gene.
Apply it
A valid result of 0.0025% IS with 40,000 ABL1 transcripts supports MR4.5. An undetectable result with 20,000 supports MR4 but cannot establish MR4.5. An undetectable sample with only 6,000 ABL1 transcripts supports neither category because its evaluable material is inadequate.
Common pitfall: Undetectable does not mean zero leukemic cells. Low target signal, transcript suitability, International Scale calibration and sample-specific control adequacy must all support the claimed category.
2025 European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia
44.Why does a clonal Ig or TCR result not prove malignancy?
Clonality testing identifies restricted antigen-receptor rearrangement patterns, which indicate a dominant lymphoid population rather than malignancy by themselves. Reactive immune responses can produce dominant clones, and limited template can generate pseudoclonal patterns. Results must be integrated with morphology, immunophenotype and clinical findings. Reproducibility and assessment across appropriate targets help interpret suspicious patterns. The decisive distinction is between evidence of a population's molecular relatedness and evidence that the population represents a neoplastic disease process in the patient.
Apply it
A small biopsy with reactive morphology yields a dominant TCR peak. Review cellularity, reproducibility, immunophenotype and clinical context before diagnosing lymphoma, because a restricted reactive population or low-template artifact can generate a seemingly clonal molecular result.
Common pitfall: Clonal is not synonymous with malignant. A compelling molecular peak cannot replace the integrated diagnostic evidence needed to establish a lymphoid neoplasm.
EuroClonality/BIOMED-2 Guidelines for Interpretation and Reporting of Ig/TCR Clonality Testing
45.How can a lymphoid neoplasm produce a negative clonality assay?
A clonality assay can miss a neoplastic population when tumor content is low, DNA is poor or the rearrangement is not efficiently amplified by the assay's primers. Somatic sequence changes can also interfere with relevant primer binding. A negative result therefore does not independently exclude lymphoma. Assess specimen adequacy and assay scope alongside morphology and immunophenotype, and consider complementary targets or testing when the integrated findings remain suspicious despite an unrevealing molecular rearrangement pattern.
Apply it
A biopsy has convincing morphologic and immunophenotypic evidence of lymphoma, but an Ig rearrangement assay is negative. Review template quality, tumor fraction and primer coverage before allowing the molecular negative to overturn the integrated diagnosis in this specimen.
Common pitfall: A negative molecular adjunct has limited exclusion power when its target or specimen is unsuitable. Failure to detect clonality is not proof of polyclonal biology.
EuroClonality/BIOMED-2 Guidelines for Interpretation and Reporting of Ig/TCR Clonality Testing
Pharmacogenetics5%
37.How does TPMT deficiency change thiopurine toxicity and prescribing decisions?
TPMT methylates mercaptopurine, diverting substrate from formation of active thioguanine nucleotides. Two no-function TPMT alleles predict poor metabolism and excessive active metabolites at standard doses, with potentially life-threatening myelosuppression. This is a non-CYP enzyme mechanism. The [CPIC thiopurine guideline](https://files.cpicpgx.org/data/guideline/publication/thiopurines/2026/41618934.pdf) distinguishes malignant from nonmalignant treatment settings and incorporates NUDT15 status.
Apply it
Before azathioprine for a nonmalignant inflammatory disorder, testing identifies two no-function TPMT alleles with normal NUDT15 function. Consider a nonthiopurine immunosuppressant rather than a standard azathioprine starting dose. For malignancy requiring mercaptopurine, CPIC instead describes a tenfold starting-dose reduction and administration three days weekly, followed by adjustment to myelosuppression and the disease protocol.
Common pitfall: Normal TPMT does not exclude NUDT15-mediated intolerance. Genotype-guided starting treatment also does not replace blood-count monitoring or adjustment for observed toxicity.
40.How does HLA-B*57:01 change an abacavir treatment decision?
HLA-B*57:01 predisposes to abacavir hypersensitivity through immune recognition rather than altered drug clearance. Abacavir can occupy the peptide-binding groove and change which self-peptides are presented, enabling a T-cell response. The [CPIC abacavir guidance](https://files.cpicpgx.org/data/guideline/publication/abacavir/2014/24561393-supplement.pdf) explains this mechanism; the [FDA pharmacogenetic associations table](https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations) directs against abacavir use in patients positive for HLA-B*57:01.
Apply it
An abacavir-naive patient has one HLA-B*57:01 allele. Select an alternative drug rather than lowering the abacavir dose or requiring homozygosity before acting. One risk allele is sufficient for the prescribing restriction.
Common pitfall: A positive genotype predicts susceptibility, not inevitable clinical hypersensitivity. A negative result does not eliminate the need to assess a subsequent compatible reaction clinically.
Molecular Genetic Pathology Content Specifications — Final · Naming Alleles — WHO HLA Nomenclature
46.Why must CYP2D6 copy-number gain be assigned to a specific allele?
An extra CYP2D6 copy changes predicted activity according to the function of the duplicated allele. Total copy number alone cannot distinguish duplication of a functional allele from duplication of a nonfunctional allele in a mixed genotype. Allele assignment and structural interpretation are therefore needed before deriving a defensible activity estimate. The enduring phasing principle should be applied using current phenotype translation and prescribing guidance rather than older phenotype labels from historical technical examples or obsolete treatment recommendations.
Apply it
A person has one functional CYP2D6 allele, one nonfunctional allele and three total copies. Determine which allele is duplicated before assigning activity, because duplicating the functional allele and duplicating the nonfunctional allele have different implications for predicted metabolism.
Common pitfall: Three copies do not automatically mean ultrarapid metabolism. Copy count, allele function and structural phase must be interpreted together using current translation conventions.
2015 CPIC SSRI Guideline Supplement · 2023 CPIC Guideline for Serotonin Reuptake Inhibitor Antidepressants
47.Which mitochondrial pharmacogenetic finding is relevant to aminoglycoside-associated hearing loss?
The mitochondrial MT-RNR1 m.1555A>G variant is associated with susceptibility to hearing loss, particularly following aminoglycoside exposure. It illustrates a drug-response association involving mitochondrial ribosomal RNA rather than a CYP metabolizer phenotype. The UK mitochondrial testing guideline identifies this variant as a testing target for nonsyndromic sensorineural hearing loss, especially when onset followed aminoglycoside treatment. Its mitochondrial location also makes maternal family history relevant.
Apply it
Several maternally related relatives developed hearing loss, including one after aminoglycoside treatment. MT-RNR1 assessment addresses a relevant susceptibility mechanism that CYP2D6 copy-number testing would not evaluate.
Common pitfall: A negative targeted m.1555A>G result excludes neither all genetic causes of hearing loss nor all drug-related ototoxicity. State the actual variant coverage.
48.How do CYP2D6 poor-metabolizer recommendations differ for paroxetine and fluvoxamine?
CPIC 2023 gives CYP2D6 poor metabolizers a moderate recommendation to consider a 50% lower paroxetine starting dose, slower titration and a 50% lower maintenance dose than for normal metabolizers. For fluvoxamine, the recommendation is optional: consider a 25–50% lower starting dose with slower titration, or an appropriate alternative not predominantly metabolized by CYP2D6. Both concern increased exposure and adverse-effect risk, but the drug-specific evidence supports different recommendation strengths.
Apply it
A poor-metabolizer result should not generate an identical instruction for both drugs. Apply the paroxetine starting and maintenance reductions separately from the fluvoxamine starting-dose or alternative-drug choice. Review interactions and age, renal and hepatic function. Inhibitors can also lower activity below a genotype-based prediction, causing phenoconversion.
Common pitfall: A shared metabolizer phenotype does not establish identical dosing across a therapeutic class. Recommendation strength and the affected dosing stage both matter.
2023 CPIC Guideline for Serotonin Reuptake Inhibitor Antidepressants
Infectious Disease6%
49.Which patients and diagnostic algorithms support appropriate C. difficile testing?
For adults, the preferred testing population has unexplained, new-onset diarrhea with at least three unformed stools in 24 hours. NAAT detects a toxigenic-organism target without independently establishing toxin-mediated disease. Without preagreed stool-submission criteria, use a toxin-containing multistep algorithm, such as GDH plus toxin with NAAT arbitration or NAAT plus toxin; with appropriate criteria, NAAT alone or a multistep algorithm is supported. Pediatric selection differs: no routine testing at ≤12 months; at ages 1–2 years, exclude other causes first; at ≥2 years, assess prolonged or worsening diarrhea with relevant risks or exposures.
Apply it
An adult service accepts specimens without enforcing symptom criteria. Use a toxin-containing multistep approach and improve selection. An infant with frequent loose stools should not enter the adult algorithm automatically because asymptomatic carriage changes the meaning of a positive result.
Common pitfall: A NAAT-positive, toxin-negative pattern requires clinical interpretation. It does not automatically establish active infection or harmless carriage, and adult stool-frequency criteria cannot be applied universally to infants.
SHEA/IDSA Clinical Practice Guideline for Clostridium difficile Infection
50.Why is C. difficile NAAT unsuitable as a routine test of cure?
Molecular positivity can persist after clinical recovery from C. difficile infection, so repeat NAAT does not reliably establish whether treatment has succeeded. Resolution of symptoms and appropriate clinical assessment are more informative than requiring nucleic-acid clearance. New compatible symptoms may justify a fresh diagnostic evaluation, but routine testing of an asymptomatic recovered patient answers a different and usually unhelpful question. Distinguish persistent detection from evidence of ongoing symptomatic infection or a clinically meaningful recurrence.
Apply it
A patient's diarrhea resolves after treatment, but a repeat NAAT remains positive. Do not define treatment failure from that result alone; interpret recovery clinically and reserve renewed diagnostic assessment for a compatible subsequent illness rather than persistent molecular detection.
Common pitfall: A positive molecular result after recovery is not equivalent to relapse. Requiring a negative NAAT can lead to unnecessary testing and inappropriate additional treatment.
SHEA/IDSA Clinical Practice Guideline for Clostridium difficile Infection
51.What does a targeted resistance-gene assay establish?
A targeted resistance assay establishes whether specified genetic determinants are detected within its validated scope. It does not survey every possible resistance mechanism, and a negative result cannot establish universal antimicrobial susceptibility. Organism context, specimen type and phenotypic results may affect interpretation. Conversely, detection of a resistance gene identifies a mechanism but should be communicated within the assay's intended use. The critical distinction is between absence of the tested determinant and absence of resistance by any mechanism.
Apply it
An isolate is phenotypically resistant, but a PCR targeting KPC and NDM is negative with valid controls. Consider other resistance mechanisms rather than dismissing the phenotype, because the assay addressed only its specified genetic targets in that organism.
Common pitfall: A negative targeted resistance panel is not a comprehensive susceptibility result. The report should name the tested determinants rather than imply that all mechanisms were excluded.
Laboratory Testing for KPC and NDM in Gram-negative Bacteria — CDC · Molecular Genetic Pathology Content Specifications — Final
52.How should serial viral RNA measurements be interpreted during treatment monitoring?
Viral monitoring uses quantitative nucleic-acid measurements to follow an established infection over time. HIV is a representative application. Compare results using consistent units, appropriate specimen type and validated quantitative performance. Detection and accurate quantification have different limits: a target can be detected below the range in which its concentration is reliably assigned.
Apply it
In a hypothetical HIV RNA series measured comparably, a fall from 100,000 to 1,000 copies/mL is a 100-fold, or 2 log10, reduction. A subsequent result of detected below the quantification limit establishes low-level detection but does not justify inventing an exact concentration or replacing the result with not detected.
Common pitfall: A quantitative decline measures change in the sampled analyte. It does not establish eradication, and an isolated result should not be interpreted without the serial pattern and assay limits.
Molecular Genetic Pathology Content Specifications — Final · Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions
Identity Testing4%
53.How is donor chimerism calculated from informative STR signals?
An informative STR locus distinguishes donor and recipient alleles sufficiently for the validated calculation. Under a simplified model using corrected donor-specific and recipient-specific peak areas, donor fraction equals donor area divided by their sum. Shared alleles, stutter, amplification imbalance and low-level detection limits can complicate real specimens. Multiple informative loci and appropriate analytical rules strengthen interpretation. The resulting percentage describes the tested cell population or specimen and does not automatically represent every hematopoietic lineage.
Apply it
At a fully informative locus, corrected donor-specific peak area is 720 and recipient-specific area is 280. The simplified donor fraction is 720 divided by 1,000, or 72%, for the tested specimen under the stated calculation assumptions.
Common pitfall: A peak near an expected stutter position may not represent a minor recipient population. Informative allele selection and validated artifact handling must precede calculation.
54.How does maternal contamination complicate prenatal molecular testing?
A prenatal specimen may contain maternal cells, causing detected alleles to reflect a mixture rather than the fetus alone. Informative polymorphic markers compared with maternal material can help assess contamination, subject to the method's sensitivity and interpretive criteria. The concern is especially important when an apparent fetal result could be explained by maternal DNA. Specimen identity, contamination assessment and disease-specific testing answer related but distinct questions and should be interpreted together before issuing a definitive prenatal conclusion.
Apply it
A prenatal specimen shows the mother's heterozygous disease-associated allele at low level. Compare informative identity markers with maternal material to assess contamination before deciding whether the fetus inherited that allele or the signal arose from maternal cells.
Common pitfall: Detecting maternal alleles does not automatically establish fetal inheritance. Conversely, uninformative shared markers cannot provide the same reassurance as a suitably informative contamination assessment.
Molecular Genetic Pathology Content Specifications — Final · Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions
Histocompatibility2%
55.What information do HLA allele fields and expression suffixes convey?
In current HLA nomenclature, the first field identifies the allele group and the second distinguishes protein sequence differences. Additional fields distinguish synonymous coding changes and differences outside coding regions. Expression suffixes add separate information; for example, N denotes a null allele. These distinctions explain why low-resolution agreement does not establish identity at every sequence or expression level. Interpret the reported resolution and suffix explicitly rather than treating every shared first field as a complete molecular match.
Apply it
Two HLA results share the first two fields but differ in a later field, and one includes an N suffix. Recognize that protein-group similarity and expression status are different pieces of information requiring explicit interpretation in compatibility assessment.
Common pitfall: An N suffix is not another numeric resolution field. Matching the first field alone also does not establish identity of the encoded HLA protein.
Informatics4%
56.How do raw-read, alignment and variant files differ?
Sequencing workflows represent different stages of analysis in different file types. Raw-read files contain base calls and associated quality information; alignment formats such as SAM, BAM and CRAM represent reads in relation to a reference; VCF records variant calls and annotations. Each stage can lose or transform information relevant to review. A variant file alone does not show every read-level feature, so investigating a suspicious call may require examining alignments or earlier data with suitable tools.
Apply it
A reviewer wants to assess strand support and local read placement around a questionable indel. Open the alignment data rather than relying only on the VCF record, which summarizes the call without displaying the complete supporting read pattern.
Common pitfall: A VCF is not a raw sequencing archive. Absence of a VCF entry does not prove that a region was adequately sequenced or confidently reference.
HTS Format Specifications — GA4GH/Samtools · Variant Call Format Specification, Version 4.5
57.Why must a variant be tied to its reference assembly?
A genomic coordinate has meaning only in relation to a defined reference sequence and coordinate convention. The same chromosome-position pair can refer to different sequence contexts across assemblies, while equivalent indels may have alternative representations within repetitive sequence. VCF metadata and reference alleles help anchor interpretation. Before comparing calls or importing annotations, verify the reference, coordinates and representation rather than assuming matching numbers establish identity or differing numbers necessarily establish different biological alterations.
Apply it
Two databases disagree on a variant's chromosome position. Check their reference assemblies and reference alleles, then use a validated mapping and representation comparison before concluding that one database contains an erroneous or biologically different variant record.
Common pitfall: Changing an assembly label does not convert coordinates. Mapping must preserve sequence context, and some loci cannot be transferred reliably without additional review.
58.How should a bioinformatics update be evaluated before clinical use?
A pipeline update can change alignment, variant detection, filtering or annotation even when the wet-laboratory procedure is unchanged. Evaluation should target the functions altered by the update and include representative challenging variants and prior failure modes. Version tracking supports reproducibility and investigation. The key question is whether the revised system maintains the performance needed for its intended clinical claims, rather than whether it produces more calls or a superficially similar overall call count on a few uncomplicated samples.
Apply it
A new aligner improves overall mapping statistics but changes calls near repetitive indels. Compare appropriate truth materials and challenging historical specimens before release, focusing on whether the affected variant class retains validated clinical performance rather than accepting the global metric alone.
Common pitfall: An unchanged gene list does not mean an unchanged assay. Software changes can alter sensitivity and specificity without any modification to primers, reagents or instruments.
AMP/CAP Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels · General Management and Informatics Content Specifications — March 2026
Management and Informatics-General3%
59.How must United States CLIA proficiency-testing samples be handled?
Under United States CLIA requirements, laboratories must test proficiency-testing samples in the same manner as patient specimens using their routine personnel and methods. Prohibited conduct includes interlaboratory communication about results before the event cutoff and referral of proficiency-testing samples to another laboratory for analysis. A difficult sample does not create an exception to these requirements. Recognize the difference between legitimate internal routine processing and actions that compromise the independent assessment of the enrolled laboratory's own performance.
Apply it
A laboratory cannot resolve a proficiency-testing sample and considers sending it to a reference laboratory used for some patient tests. Do not refer the proficiency-testing sample; handle the event under the laboratory's procedures and applicable CLIA requirements.
Common pitfall: Routine patient referral practices do not authorize referral of proficiency-testing samples. Informal comparison with another laboratory before the deadline also compromises independent proficiency assessment.
clia-brochure-proficiency-testing-and-pt-referral-october-2024.pdf
60.How do root-cause analysis and change control prevent repeated errors?
Root-cause analysis examines how a process allowed an error, extending beyond the immediate action of one individual. Corrective action should address the identified mechanism and include a way to assess effectiveness. Change control documents evaluation, approval and implementation of modifications that could affect laboratory performance or information integrity. Together, these practices connect an observed failure to a controlled improvement rather than relying on a reminder or an undocumented workaround that may leave the original vulnerability in place.
Apply it
Several reports acquire the wrong transcript after an information-system update. Investigate mapping and interface behavior, assess affected reports, correct the controlled configuration and verify effectiveness rather than limiting the response to retraining the person who released the latest report.
Common pitfall: Retraining alone cannot repair a faulty interface rule. Closing an investigation without checking whether the corrective action works leaves recurrence risk unmeasured and potentially unchanged.
General Management and Informatics Content Specifications — March 2026 · Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Connect specimen quality, tumor fraction, alteration class and detection limit before interpreting a negative molecular result.
- Practise explicit Bayesian, allele-fraction and informative-STR calculations, stating the assumptions that make each calculation valid.
- Distinguish DNA findings from demonstrated RNA effects, gene dosage from phase, and tumor findings from germline status.
- Give inherited diseases, solid tumors and hematopathology proportionally greater study time while retaining every smaller weighted domain.
- Interpret colorectal RAS and MMR findings, lung MET skipping and breast HER2 results using their specific diagnostic or treatment questions.
- Interpret CML measurements using transcript suitability, International Scale thresholds and sample-specific sensitivity; distinguish these monitoring tasks from acute-leukemia alteration classes and integrated MPN diagnosis.
- Apply medication-specific pharmacogenetic recommendations across CYP metabolism, TPMT-mediated thiopurine toxicity, HLA-associated hypersensitivity and mitochondrial drug susceptibility.
- Review pedigrees, sequencing traces, array patterns, amplification controls, viral-load series and genomic file metadata alongside text-based questions.
- Use the complete official specifications to extend beyond these selected concepts, including additional inherited disorders, organ-specific biomarkers, myeloid and lymphoid alterations, immunogenetics and gene therapy.
A practical preparation plan
1. Map the full subspecialty scope
Read the 2026 weighted blueprint beside the final detailed specifications. Mark foundational topics already secure and fellow-level interpretation tasks needing work. Allocate study sessions approximately by domain weight, with recurring coverage of all 17 domains.
2. Build a mechanism-to-method map
For each disorder or biomarker, connect the causal mechanism to the specimen and method that can detect it. Record important blind spots: balanced rearrangements on arrays, silent SMN1 carriers, large repeats, methylation abnormalities and expressed splice or fusion events.
3. Work through quantitative decisions
Calculate residual carrier risk, expected tumor allele fraction and donor chimerism from explicit inputs. Explain how copy number, phase, assay sensitivity or uninformative markers would invalidate a shortcut. Assign deep CML response only when both the International Scale result and reference-transcript minimum support it.
4. Practise integrated result interpretation
For each case, state what the assay establishes, what remains unresolved and which finding changes the conclusion. Integrate clonality with morphology, tumor biomarkers with treatment context and inherited findings with family structure. Work through uncertain-variant classification, parent-of-origin studies and viral monitoring rather than memorizing labels alone.
5. Review laboratory failure and governance cases
Interpret internal controls, contamination patterns, quantitative drift and limited coverage. Then practise proficiency-testing rules, consent boundaries, software change control and report correction using the relevant clinical or regulatory source.
6. Use drills to direct the next review
Answer the independent questions before reading explanations, then explain every alternative. Use flashcards for spaced recall and return missed mechanisms to the official outline. Track reasoning errors rather than treating a short practice score as a pass estimate.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- Molecular Genetic Pathology — ABPath
- 2026 ABPath Booklet of Information
- Subspecialty Exam Blueprints and Daily Exam Schedules — ABPath
- Molecular Genetic Pathology Exam Blueprint — Updated for 2026
- Content Specifications for Examinations — ABPath
- Molecular Genetic Pathology Content Specifications — Final
- General Management and Informatics Content Specifications — March 2026
- RNA Splicing — HGVS Nomenclature
- Glossary — HGVS Nomenclature
- Consensus Statement: Chromosomal Microarray Is a First-Tier Clinical Diagnostic Test
- AMP/CAP Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels
- Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions
- Laboratory Testing for KPC and NDM in Gram-negative Bacteria — CDC
- Genetic Testing FAQ — NHGRI
- Laboratory Testing for Fragile X, 2021 Revision — ACMG Technical Standard
- FMR1 Disorders — GeneReviews
- Spinal Muscular Atrophy — GeneReviews
- Pan-ethnic Carrier Screening and Prenatal Diagnosis for Spinal Muscular Atrophy
- Recurrence and Variability of Germline EPCAM Deletions in Lynch Syndrome
- BRCA Gene Changes: Cancer Risk and Genetic Testing — NCI
- ASCP/CAP/AMP/ASCO Colorectal Cancer Molecular Biomarkers — Summary of Recommendations
- The Landscape of MET Exon 14 Skipping Mutations in Patients With Lung Cancer
- 2025 European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia
- EuroClonality/BIOMED-2 Guidelines for Interpretation and Reporting of Ig/TCR Clonality Testing
- 2015 CPIC SSRI Guideline Supplement
- 2023 CPIC Guideline for Serotonin Reuptake Inhibitor Antidepressants
- SHEA/IDSA Clinical Practice Guideline for Clostridium difficile Infection
- Hematopoietic Chimerism Monitoring Based on STRs
- Naming Alleles — WHO HLA Nomenclature
- HTS Format Specifications — GA4GH/Samtools
- Variant Call Format Specification, Version 4.5
- 42 CFR 493.801 — Enrollment and Testing of Proficiency Testing Samples
- Technical standards and guidelines for spinal muscular atrophy testing | Genetics in Medicine
- s41431-019-0435-0.pdf
- s41431-022-01249-w.pdf
- clia-brochure-proficiency-testing-and-pt-referral-october-2024.pdf
- Numbering - HGVS Nomenclature
- s41436-021-01115-y.pdf
- 320196.pdf
- Standards_Guidelines_for_the_Interpretation_of_Sequence_Variants.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.